百乐眠胶囊联合α-受体阻滞剂治疗良性前列腺增生症引起的夜尿症

目的:观察百乐眠胶囊联合α-受体阻滞剂治疗良性前列腺增生症引起的夜尿症的疗效。方法:随机选取符合良性前列腺增生症诊断,采用α-受体阻滞剂单药治疗,夜尿仍大于等于2次的患者20例,在继续服用α-受体阻滞剂治疗的基础上,加用百乐眠胶囊,每日2次,每次4粒。加用百乐眠胶囊前和用药1个月后,分别采用国际前列腺症状评分表(International Prostate Symptom Score,IPSS),生活质量指数(quality of life index,QoL),膀胱过度活动症评分表(Overactive Bladder Symptom Score,OABSS)进行评估。结果:加用百乐眠胶囊1月后,IPSS评分表中夜尿评分从2.88降至2.41(P=0.03),OABSS评分表总分从6.31降至5.38(P=0.03),夜尿评分从2.63降至2.13(P=0.01),QoL评分无显著变化。结论:百乐眠胶囊联合α-受体阻滞剂治疗良性前列腺增生症引起的夜尿症有较好的疗效。     

老年良性前列腺增生夜尿病因特点及相关因素分析

目的:探索老年良性前列腺增生夜尿病因特点及相关因素。方法:选取49~84岁年龄段并已明确诊断为前列腺增生(BPH)的男性患者及没有进行过治疗或服用药物者120例。所有患者按照IPSS评分中夜尿频率从0~5分为6组,记录和测量研究对象的各项指标,包括国际前列腺症状评分(IPSS)、生活质量(QOL)、剩余尿量(PVR)、最大尿流率(Qmax)、前列腺体积(TPV)和排尿量(V)。结果:夜尿频率为0~1次者共38例(31.7%),平均QOL评分为2.43;夜尿频率为2~3次者共50例(41.7%),平均QOL评分为3.87;夜尿频率为4次以上者共32例(26.7%),平均QOL评分为5.23。不同组的夜尿频率BPH患者间的QOL评分具有显著性差异(P0.05);多因素Logistic回归分析表明,BPH患者的年龄和PVR是夜尿频率增高的危险因素(P0.05),而TPV和Qmax与夜尿频率的关系无统计学意义(P0.05)。结论:夜尿频率的增多明显影响老年人的生活质量,并且随着老年人的年龄、残余尿量的增加,夜尿频率出现增加的趋势;但前列腺的体积和最大尿流率与夜尿频率无关。     

非那雄胺联合M受体拮抗剂治疗前列腺增生合并膀胱过度活动症的疗效

目的:探讨非那雄胺联合M受体拮抗剂对前列腺增生合并膀胱过度活动症临床疗效的影响。方法:回顾性研究我院前列腺增生合并膀胱过度活动症的患者60例,随机分为实验组和对照组,每组30例。对照组患者给予M受体拮抗剂,实验组患者在对照组的基础上给予非那雄胺。观察并比较治疗前后两组患者国际前列腺症状评分(IPSS)、膀胱过度活动症评分(OABSS)、残余尿量、最大尿流率、尿急次数以及治疗期间不良反应。结果:与对照组相比,实验组患者IPSS及OABSS较低(P0.05);残余尿量较少,最大尿流率较大,尿急次数较少(P0.05);不良反应发生率较低(P0.05)。结论:非那雄胺联合M受体拮抗剂能够降低前列腺增生合并膀胱过度活动症的不良反应发生率,提高临床疗效,值得在临床上推广应用。     

包皮环切术联合α受体阻滞剂治疗慢性前列腺炎的临床研究

目的:探讨α-受体阻滞剂联合包皮环切术治疗慢性前列腺炎/慢性骨盆疼痛综合征(CP/CPPS)的临床疗效。方法:目标选择2016年7月至2017年10月上海市第一人民医院收治的100例年龄18～50岁的包皮过长同时合并CP/CPPS患者为研究对象,将其随机分为包皮环切术组58例和对照组52例。包皮环切术组的患者接受α-受体阻滞剂治疗的同时进行包皮环切术,对照组仅给予α-受体阻滞剂治疗。采用国际慢性前列腺炎症状指数NIH-CPSI的变化评估和比较两组的治疗效果。结果:以NIH-CPSI总分3个月从基线减少4分为治疗有效,包皮环切术组和对照组治疗有效率分别为82.6%、62.5%,包皮环切术组显著高于对照组(P0.001)。治疗12周后,包皮环切术组NIH-CPSI总分的中位数从24.0±4.0降至12.0±8.0(P0.001),对照组从24.0±3.0降至15.0±7.0(P0.001),两组比较差异具有统计学意义(P0.001)。包皮环切组NIH-CPSI总分、疼痛评分、尿路评分和生活质量评分均明显低于对照组(P0.001)。结论:与单独应用α受体阻滞剂相比,联合包皮环切术联合α-受体阻滞剂药物治疗更有效提高CP/CPPS患者的临床疗效,改善患者的慢性前列腺炎症状评分。     

650 nm激光穴位照射与针刺治疗良性前列腺增生症的疗效对比观察

目的:观察、评估650 nm激光照射穴位治疗良性前列腺增生症(中医辨证为肾阳虚)的临床疗效。方法:对30例良性前列腺增生症患者,采用650 nm激光,照射会阴、关元、肾俞,并随机选取30例,用针刺治疗作临床对比观察,针刺肾俞、秩边、关元、命门、足三里、脾俞、三阴交、次髎等穴。结果:激光照射穴位与针刺治疗均对良性前列腺增生症有较好的疗效,两组治疗前后症状评分、尿动力学均有显著的改变(P<0.05),但两者的临床疗效差异无统计学意义(P>0.05)。结论:650 nm激光穴位照射是临床治疗良性前列腺增生症(肾阳虚型)的有效治疗方法之一,值得深入研究。     

琥珀酸索利那新片治疗膀胱过度活动症的效果分析

目的:观察琥珀酸索利那新片治疗膀胱过度活动症的临床效果。方法:回顾性分析我科收治的膀胱过度活动症患者共90例,所有患者均符合由中华医学会泌尿外科分会尿控学组制定的《膀胱过度活动症临床指导原则》。其中43例患者采用酒石酸托特罗定片治疗并设为对照组,47例患者采用琥珀酸索利那新片治疗并设为观察组,对比两组患者用药前后排尿症状和尿动力学参数变化、膀胱过度活动症症状评分表(OABSS评分)和前列腺症状评分(IPSS评分)变化以及不良反应发生率对比情况。结果:观察组患者用药后平均24 h尿急次数、平均24 h排尿次数均明显低于对照组,最大尿流率(Qmax)、初始尿意容量(FDV)、最大膀胱压容量(MCBC)均明显高于对照组,两组患者以上指标相比较,差异均有显著性(P0.05);两组患者用药后OABSS评分和IPSS评分均有所下降,但是两组相比,差异不具有显著性(P0.05);3两组患者用药后均有不同程度的不良反应,其中口干症状患者比例具有差异性(P0.05)。结论:琥珀酸索利那新片治疗膀胱过度活动症疗效确切,安全性高。     

遂宁地区良性前列腺增生术后LUTS相关危险因素分析

目的:调查与分析遂宁地区良性前列腺增生术后下尿路症状(Lower Urinary Tract Symptoms,LUTS)发生的相关危险因素。方法:2014年9月到2019年10月选择在遂宁市中心医院诊治的遂宁地区良性前列腺增生症患者172例,所有患者都给予手术治疗,记录术后LUTS发生情况,调查患者的临床资料并进行影响因素分析。结果:在172例患者中,术后平均国际前列腺症状评分量表(International prostate symptom scores,IPSS)评分为5.67±0.13分,其中储尿期症状评分3.01±0.11分,排尿期症状评分为1.76±0.22分,排尿后症状评分0.89±0.14分,发生LUTS 18例(LUTS组),发生率为10.5%。LUTS组的生活质量评分高于非LUTS组(P<0.05);LUTS组的年龄、体重指数、低密度脂蛋白、总胆固醇、前列腺体积与非LUTS组对比差异有统计学意义(P<0.05);Pearson分析显示年龄、体重指数、低密度脂蛋白、总胆固醇、前列腺体积都与LUTS存在相关性(P<0.05);二元Logistic回归分析显示年龄、体重指数、低密度脂蛋白、总胆固醇、前列腺体积都为导致LUTS发生的主要因素(P<0.05)。结论:遂宁地区良性前列腺增生术后LUTS的发生比较常见,可严重影响患者的生活质量,年龄、体重指数、低密度脂蛋白、总胆固醇、前列腺体积都为导致LUTS发生的主要因素。     

HoLEP对良性前列腺增生的疗效及安全性观察

目的:探讨以尿道钬激光前列腺剜除术(HoLEP)治疗良性前列腺增生(BPH)的临床疗效和安全性。方法:选取我院102例以HoLEP术治疗的BPH患者的临床资料,分析BPH患者的年龄、切除腺体的大小、手术出血量、手术前后的最大尿流率(Qmax)、最大尿流率时逼尿肌压(Pdet/Qmax)、国际前列腺症状评分表(IPSS)评分和生活质量评分(QOLS)等。再选取我院100例以尿道前列腺电切术(TURP)治疗的BPH患者的临床资料,对比两组患者并发症的发生情况。结果:102例BPH患者的年龄为(71.58±9.74)岁,切除腺体为(84.32±36.39)g,手术出血量为(146±24.68)mL,手术前的最大尿流率(8.37±5.28)mL/s,最大尿流率时逼尿肌压为(72.93±26.49)cm H_2O,IPSS评分为(28.8±5.98)分,QOLS评分为(5.8±0.46)分;手术后的最大尿流率(24.77±5.89)mL/s,最大尿流率时逼尿肌压为(42.35±10.37)cm H_2O,IPSS评分为(9.4±1.28)分,QOLS评分为(2.8±0.28)分。手术后的Qmax明显升高(P0.05),而Pdet/Qmax、IPSS评分和QOLS均显著降低(P0.05)。HoLEP术治疗的BPH患者并发症发生明显低于尿道前列腺电切术(TURP)治疗的患者(P0.05)。结论:HoLEP是一种安全有效的治疗BPH的微创手术。     

经尿道前列腺电切(TURP)联合输尿管镜钬激光碎石术治疗前列腺增生症(BPH)合并膀胱结石的疗效观察

目的:观察分析经尿道前列腺电切(TURP)联合输尿管镜钬激光碎石术治疗前列腺增生症(BPH)合并膀胱结石的效果。方法:本组61例患者先行膀胱结石钬激光碎石,然后采用经尿道前列腺电切术(TURP)治疗前列腺增生症。结果:61例一次性治疗成功,术后结石无残留,排尿情况较前明显改善,IPSS评分均分由24.4分降到9.4分,最大尿流率由7.2 mL/s上升到19.5 mL/s。结论:钬激光碎石及TURP同期治疗前列腺增生合并膀胱结石是安全有效的方法。     

硝苯地平片联合酒石酸托特罗定片对TURP术后膀胱过度活动症的应用效果分析

目的:探讨硝苯地平片联合酒石酸托特罗定片用于经尿道前列腺电切术(TURP)术后膀胱过度活动症的临床效果及安全性。方法:选择2015年8月至2017年8月我院接诊的103例TURP术后出现膀胱过度活动症的患者作为本研究对象,通过随机数表法将其分为试验组52例和对照组51例。两组均给予常规处理,对照组在此基础上口服酒石酸托特罗定片,2 mg/次,2次/d;试验组在对照组基础上联合硝苯地平片口服,5 mg/次,3次/d;两组均连续用药7d。比较两组临床疗效,治疗前后膀胱过度活动症(OABSS)评分、国际前列腺症(IPSS)评分、膀胱痉挛次数、排尿情况的变化以及不良反应的发生情况。结果:治疗后,试验组和对照组临床疗效总有效率分别为92.31%(48/52)和76.47%(39/51),OABSS评分分别为(2.69±0.58)分和(4.76±0.62)分,IPSS评分分别为(5.02±0.80)分和(7.86±1.15)分,24h膀胱痉挛次数分别为(0.65±0.48)次和(1.10±0.61)次,24h尿急次数分别为(0.88±0.32)次和(1.59±0.54)次,24h排尿次数分别为(5.52±1.02)次和(7.24±0.97)次,夜间排尿次数分别为(0.73±0.45)次和(1.39±0.70)次,24 h平均尿量分别为(227.07±16.68)mL和(196.65±15.07)mL,试验组临床总有效率和24 h平均尿量均显著高于对照组(P0.05),OABSS评分、IPSS评分、24 h膀胱痉挛次数、24 h尿急次数及24h排尿次数均显著低于对照组(P0.05)。两组不良反应发生率比较差异无统计学意义(P0.05)。结论:硝苯地平片联合酒石酸托特罗定片治疗TURP术后膀胱过度活动症患者的临床疗效明显优于单用酒石酸托特罗定片,其可更有效促进膀胱功能恢复,且不增加不良反应。     

Increased Serum C-Reactive Protein Level Is Associated with Increased Storage Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia

Objective

Chronic inflammation is considered as one of the contributing mechanisms of lower urinary tract symptoms (LUTS). Serum C-reactive protein (CRP) level is the widely used biomarker of inflammatory status. This study investigated the association between serum CRP level in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) before and after medical treatment.

Methods

A total of 853 men with BPH and LUTS were enrolled. All patients completed the International Prostate Symptoms Score (IPSS) questionnaire and urological examinations. The parameters of uroflowmetry (maximum flow rate, Qmax; voided volume, VV), post-void residual (PVR), total prostate volume (TPV) and transition zone index (TZI), serum prostate specific antigen (PSA), and serum CRP levels were obtained. All patients were treated with alpha-blocker or antimuscarinic agent based on the IPSS voiding to storage subscore ratio (IPSS-V/S). Correlation analyses were performed between serum CRP levels with age, IPSS, TPV, TZI, Qmax, PVR, VV, PSA and between baseline and post treatment.

Results

The mean age was 66.9±11.6 years old and the mean serum CRP levels were 0.31±0.43 mg/dL. Univariate analyses revealed serum CRP levels were significantly associated with age (p<0.001), PSA levels (p = 0.005) and VV (p = 0.017), but not significantly associated with TPV (p = 0.854) or PVR (p = 0.068). CRP levels were positively associated with urgency (p<0.001) and nocturia (p<0.001) subscore of IPSS, total IPSS (p = 0.008) and storage IPSS (p<0.001) and negatively associated with IPSS- V/S ratio (p = 0.014). Multivariate analyses revealed that serum CRP levels were significantly associated with age (p = 0.004) and storage IPSS subscore p<0.001). Patients with IPSS-V/S<1 and treated with tolterodine for 3 months had significant decrease of CRP levels after treatment.

Conclusion

Serum CRP levels are associated with storage LUTS and sensory bladder disorders, suggesting chronic inflammation might play a role in the patients with storage predominant LUTS.     

血清PSA、EGF在不同类型良性前列腺增生患者中表达意义及其与术后疾病转归的相关性分析

摘要 目的：分析血清前列腺特异抗原（PSA)、表皮生长因子（EGF)在不同类型良性前列腺增生患者中低表达意义及其与术后疾病转归的相关性。方法：选择自2020年1月至2022年12月在我院接受手术治疗的128例良性前列腺增生患者作为研究对象,根据术后病理活检结果进行分组,间质结节组（16例）、腺肌性结节组（32例）、纤维腺瘤性结节组（12例）、腺性结节组（30例）和混合结节组（38例）,其中以间质增生为主60例、以腺体增生为主68例。检测所有患者血清PSA、EGF的表达水平,以术后6个月的国际前列腺症状评分（IPSS评分）<8分判定为预后良好,分析血清PSA、EGF在预后良好组与预后不良组之间的差异性及与IPSS评分的关系。结果：血清PSA、EGF表达水平在间质结节组、腺肌性结节组、纤维腺瘤性结节组、腺性结节组和混合结节组间比较有差异（P<0.05）;以腺体增生为主的良性前列腺增生患者血清PSA、EGF表达水平均明显高于以间质增生为主的患者（P<0.05）;经ROC曲线分析,血清PSA联合EGF预测以腺体增生为主的良性前列腺增生的敏感度为86.42%,特异度为65.34%,AUC为0.930;所有患者均获得随访6个月,预后良好98例、预后不良30例;预后不良组血清PSA、EGF表达水平均明显高于预后良好组（P<0.05）;经Pearson相关性分析,良性前列腺增生患者血清PSA、EGF表达水平均与IPSS评分呈负相关（r值分别为-0.348、-0.417,P值均为0.000）。结论：血清PSA、EGF在不同病理类型良性前列腺增生患者中表达差异显著,以间质增生为主的患者,以腺体增生为主的患者血清PSA、EGF表达水平更高,两者均与术后疾病转归密切相关,值得临床予以重视。     

尿道等离子电切和弹道超声碎石治疗前列腺增生症并膀胱结石的临床疗效观察

目的:探讨尿道等离子电切和弹道超声碎石治疗前列腺增生症并膀胱结石临床效果及安全性。方法:选择本院2012年1月~2013年8月本院泌尿外科收治的84例前列腺增生症并膀胱结石患者,观察患者的手术时间、术中出血量、住院时间、并发症、IPSS评分、QOL、PVR、Qmax。结果:84例患者手术均获成功,平均出血量(118.94±11.57)mL;平均手术时间(74.19±5.68)min;平均导尿管拔除(7.38±1.17)d;住院时间(18.65±2.41)d。术后3个月,患者IPSS评分、QOL、PVR、Qmax分别为(7.18±1.40)分、(1.54±0.32)、(19.01±4.26)mL和(23.06±4.19)mL/s,术前分别为(23.61±3.24)分、(4.44±0.81)、(108.52±9.37)mL和(5.82±0.74)mL/s,差异具有显著性统计学意义(P0.05)。结论:尿道等离子电切和弹道超声碎石治疗前列腺增生症并膀胱结石安全、有效、手术彻底且术后恢复快。     

Correlation of Prostatic Urethral Angle with the Severity of Urinary Symptom and Peak Flow Rate in Men with Small Prostate Volume

Purpose

To evaluate the effects of prostatic anatomical factors on male lower urinary tract symptoms (LUTS) and the peak flow rate (Qmax) in patients with small prostate volume (PV).

Materials and Methods

Records were obtained from a prospectively maintained database of first-visit men with LUTS. Patients whose total PV (TPV) was greater than 30 mL were excluded; 444 patients were enrolled in the study. The TPV, transitional zone volume (TZV), transitional zone index (TZI), intravesical prostatic protrusion (IPP), and prostatic urethral angle (PUA) were measured by transrectal ultrasonography. LUTS were evaluated using the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS) questionnaires. Uroflowmetric measurements were also made.

Results

PUA (r = 0.269, P<0.001), TZV (r = 0.160, P<0.001), and TZI (r = 0.109, P = 0.022) significantly correlated with the IPSS. Qmax (r = −0.334, P<0.001) and OABSS (r = 0.211, P<0.001) correlated only with PUA. In a multivariate regression analysis, PUA and age were independently associated with IPSS, OABSS, and Qmax. For IPSS of 20 or greater, the area under the ROC curve (AUC) of PUA was 0.667 and the cut-off value was 43.7°. When Qmax was 10 mL/s or less, the AUC of PUA was 0.664 and the cut-off value was 43.5°.

Conclusions

PUA has a significant association with symptom severity and Qmax among prostatic anatomical factors analyzed in men with LUTS and small PV. PUA should be considered as an important clinical factor in male LUTS management. Furthermore, the impact of PUA on response to medical treatment and disease progression needs to be investigated.     

Résultats fonctionnels de la radiofréquence par Prostiva? dans le traitement de l’hypertrophie bénigne de la prostate (HBP) non compliquée résistante aux traitements médicamenteux

Objective

To assess prospectively on objective and subjective parameters functional outcomes of prostatic thermotherapy by radiofrequency (Prostiva?) on urinary discomfort and sexual life in the treatment of uncomplicated symptomatic and resistant to drug treatment benign prostatic hypertrophy (BPH).

Patients and methods

Patients with eligibility criteria for this treatment published by HAS have been treated in our urology unit. They were called at one month for a clinical examination and analysis of objective data (maximum urine flow [Qmax], post-voiding residual, international prostate score symptom [IPSS]). They were contacted in December 2009 and submitted to a questionnaire on urinary symptoms (IPSS), quality of life (question 8 of IPSS), assessment of sexual function (IIEF, DAN SEX) and subjective assessment of treatment (Likert score).

Results

From December 2006 to January 2009, 20 patients (median age: 63 years) were treated with Prostiva?. Four patients had acute retention of urine in the immediate postoperative needing a urinary catheterization in emergency. We made a systematic evaluation of all patients at one month and in December 2009. The median follow-up was 20.6 months (12?C37 months). There was a significant improvement of IPSS (?6.7 points; IC95= [?10.3; ?3.1]), an improvement of sexuality functions, quality of life data, and a sense of global improvement of urinary symptoms (+ 1.8 = improved on the Likert score). Four patients were considered as failures: three patients resumed drug therapy, one patient received a prostate resection.

Conclusion

Our single centre study performed in selected patients according to the criteria of HAS consolidated the results of published studies. Results were positive on urinary symptoms, with a low morbidity and a positive subjective evaluation on symptoms. It demonstrated the safety of thermotherapy on patients?? sexuality and even better, the positive impact of the treatment on erections and satisfaction relations.     

The Impact of Increased Bladder Blood Flow on Storage Symptoms after Holmium Laser Enucleation of the Prostate

In order to investigate how holmium laser enucleation of the prostate (HoLEP) improves urinary storage symptoms, we assessed blood flow in the urinary bladder mucosa of patients with benign prostatic hyperplasia (BPH) before and after laser surgery. Seventy-four consecutive patients with BPH (median age 69 years, range; 53–88) underwent HoLEP at our institution and are included in this study. We prospectively assessed the International Prostate Symptom Score (IPSS), IPSS-QOL Score, the Overactive Bladder Symptom Score (OABSS), uroflowmetry, and blood flow in the urinary bladder, before and after surgery. Blood flow in the bladder mucosa was measured using the OMEGA FLOW (OMEGAWAVE, Tokyo, Japan) laser Doppler flowmeter. The median volume of the enucleated adenomas was 45.0 g (range: 25.0 to 83.2). The median IPSS improved significantly from 20 (range: 6–35) to 3 (0–22) (p<0.001; Wilcoxon signed-rank test), as did the storage symptoms score, which decreased from 13 (2–20) to 3 (1–8) (p<0.001). Median bladder blood flow increased at the trigone from 9.57±0.83 ml/sec to 17.60±1.08 ml/sec. Multiple regression analysis for the improved storage symptom score eliminated all explanatory variables except increased bladder perfusion. The data suggest that HoLEP improves blood flow in the bladder mucosa, which independently leads to the improvement of storage symptoms.     

Gender differences in health-related quality of life among healthy aged and old-aged austrians: Cross-sectional analysis

Background: Although they experience lower mortality rates and lower rates of several chronic diseases than do their male counterparts, aging women are more likely to experience functional impairment in mobility and a general diminished health-related quality of life (HRQoL). The determinants of these gender differences have been the subject of controversy.Objective: This study analyzed gender differences in HRQoL in relation to social and biomedical factors such as age, marital status, educational level, and living arrangements.Methods: Participants were recruited via snowball sampling. All were healthy and lived independently in private homes. Data were obtained from personal interviews, based on a 30-item questionnaire, in the private homes of the participants. Additionally, HRQoL was assessed by means of the abbreviated version of the World Health Organization Quality of Life (WHOQOL-BREF) 26-item questionnaire, which contains 1 general health item, 1 general QoL item, and 24 specific items covering 4 broad domains: physical (DOM I), psychological (DOM II), social (DOM III), and environmental (DOM IV).Results: The participants (98 women, 62 men) enrolled in the study ranged in age from 57 to 95 years (mean [SD] age: 71.8 [8.6] years). The younger age group (aged 57-70 years) comprised 54 women and 25 men, and the older age group (aged >70 years) comprised 44 women and 37 men. Women aged ≤70 years rated their health and QoL significantly higher than did men in the same age group (P = 0.02). These women rated physical capacity (DOM I), social relationships (DOM III), and environment (DOM IV) higher, but not statistically significantly different, than did same-aged men. Women and men exhibited nearly identical psychological health (DOM II) values. Physical capacity (DOM I) differed significantly between women and men aged >70 years (P = 0.03). Women aged >70 years rated their QoL lower than their male counterparts did, although not significantly so. These women depended more on medical treatment, felt significantly less safe in everyday life (P = 0.03), and were less satisfied with themselves.The results of the multiple regression analyses suggest that gender may have a significant impact on general QoL for both age groups (P < 0.01 for the younger age group; P > 0.04 for the older age group). In these analyses, gender also had a significant impact on 2 domains, physical capacity and social relationships (P < 0.02 for both domains), among the participants of the younger age group.Conclusion: Depending on the age group (≤70 vs >70 years) in this small sample of Austrian women and men, gender influenced HRQoL.     

钬激光电切术对老年高血压患者前列腺增生的疗效及安全性

目的:探讨钬激光和经尿道电切术治疗老年高血压伴前列腺增生的疗效和安全性。方法:回顾性分析2011年1月-2013年1月我科收治的48例患者的临床资料,随机分为两组,每组24例,分别采用经尿道前列腺电切术和激光切除术治疗。观察两组手术时间、术中出血量、住院时间、IPSS和QOL评分及血压变化情况。分别于手术前后应用经直肠超声测量患者前列腺厚度,根据球形体积公式估算前列腺重量。结果:钬激光组手术时间、术中出血量、住院时间明显低于电切组,差异具有统计学意义(P0.05);钬激光组术后前列腺重量、IPSS评分、QOL评分及血压均低于电切组,差异具有统计学意义(P0.05)。结论:经尿道钬激光切除术治疗伴高血压的老年前列腺增生患者安全有效,可在临床推广。     

TURP联合经尿道膀胱颈切开术治疗小体积前列腺增生所致膀胱出口梗阻的疗效分析

目的:探讨经尿道前列腺电切术(TURP)联合经尿道膀胱颈切开术(TUIBN)治疗小体积前列腺增生(BPH)所致膀胱出口梗阻的疗效。方法:选择2009年1月~2013年12月我院收治的小体积BPH患者,其中单纯经尿道前列腺电切术(TURP组)48例,经尿道前列腺电切术联合经尿道膀胱颈切开术(TURP+TUIBN组)48例。比较两组的术前、术后国际前列腺症状评分(IPSS)、残余尿量(PVR)、最大尿流率(Qmax)等,以及术后并发症的发生情况。结果:TURP+TUIBN组术中出血量较TURP组明显增多(P0.05),两组手术时间、组织切除质量比较,差异均无统计学意义(P0.05);与TURP组比较,TURP+TUIBN组术后6个月IPSS评分、PVR明显下降,Qmax、膀胱压力明显上升(P0.05);TURP+TUIBN组并发症发生率为4.2%,显著低于TURP组16.7%(P0.05)。结论:TURP+TUIBN治疗小体积前BPH所致膀胱出口梗阻,可彻底切除增生腺体,消除小体积BPH的各种梗阻因素,减少术后膀胱颈挛缩的发生。